Phase II study of erlotinib and docetaxel with concurrent intensity-modulated radiotherapy in locally advanced head and neck squamous cell carcinoma.
Phase II study of erlotinib and docetaxel with concurrent intensity-modulated radiotherapy in locally advanced head and neck squamous cell carcinoma.
复制标题
DOI：
10.1002/hed.24313
复制
发表时间：
2016-04
期刊：
影响因子：
--
通讯作者：
Savvides P
中科院分区：
文献类型：
--
作者：
Yao M;Woods C;Lavertu P;Fu P;Gibson M;Rezaee R;Zender C;Wasman J;Sharma N;Machtay M;Savvides P
目的：探讨厄洛替尼联合多西紫杉醇联合调强放疗治疗局部晚期头颈部鳞状细胞癌的疗效和毒副作用。患者每天接受厄洛替尼治疗两周，然后每天接受调强放疗，同时每周接受多西紫杉醇和厄洛替尼治疗，然后每天接受厄洛替尼治疗长达两年。主要目标是无病生存(DFS)。次要目标包括总存活率(OS)、失败模式和毒性。共纳入43例患者。中位随访期48.7个月，3年DFS、OS、无局部失败生存率和无远处转移生存率分别为69.5%、81%、82.4%和83.7%。最常见的III/IV级局部毒性是吞咽困难、皮炎和粘膜炎。P16+肿瘤患者的预后明显好于对照组。这种养生法是可以耐受的，而且有效。它值得在选定的患者中进行进一步研究，并可能对不能耐受顺铂的患者有用。
To establish the efficacy and toxicities of concurrent erlotinib and docetaxel with IMRT for locally advanced head and neck squamous cell carcinoma (HNSCC). Patients received daily erlotinib for two weeks, followed by daily IMRT with concurrent weekly docetaxel and daily erlotinib, followed by daily erlotinib for up to two years. The primary objective was disease-free survival (DFS). Secondary objectives included overall survival (OS), patterns of failure, and toxicities. Forty-three patients were recruited. With a median follow-up of 48.7 months, the 3 year DFS, OS, locoregional failure free survival and distant metastasis free survival was 69.5%, 81%, 82.4%, and 83.7%, respectively. The most common grade III/IV local toxicities were dysphagia, dermatitis and mucositis. Patients with P16+ tumor had significantly better outcomes. The regimen is tolerable and effective. It is worthy of further investigation in selected patients and may be useful in patients who cannot tolerate cisplatin.